218 related articles for article (PubMed ID: 30238838)
1. Critical appraisal of commercially available suspending vehicles for extemporaneous compounding of cardiovascular medicines: physical and chemical stability mini review.
Thrimawithana TR; D'Amore S; Dib Y; Fadavi Firooz N; Fakhouri W; Saeed A; Allahham A
Pharm Dev Technol; 2019 Jun; 24(5):529-538. PubMed ID: 30238838
[TBL] [Abstract][Full Text] [Related]
2. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
Pabari RM; McDermott C; Barlow J; Ramtoola Z
Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients.
Casas M; Álvarez J; Lucero MJ
Pharm Dev Technol; 2015 May; 20(3):271-8. PubMed ID: 24279906
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of the Stability of Extemporaneous Pediatric Oral Formulations.
Belayneh A; Tessema Z
ScientificWorldJournal; 2021; 2021():8523091. PubMed ID: 34955693
[TBL] [Abstract][Full Text] [Related]
5. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
Lam MS
Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
[TBL] [Abstract][Full Text] [Related]
6. Compounded medications for cardiovascular use in neonatology: an integrative review.
Greenhalgh LL; Passos MMBD; Agrizzi AL; Monteiro MSSB
Rev Paul Pediatr; 2022; 41():e2021167. PubMed ID: 36102396
[TBL] [Abstract][Full Text] [Related]
7. Improving policies and practices for the extemporaneous compounding of oral liquid dosage forms in Saudi Arabian hospitals.
Joosub I; Emara Z; Gray A
Eur J Hosp Pharm; 2021 Sep; 28(5):280-283. PubMed ID: 34426482
[TBL] [Abstract][Full Text] [Related]
8. Patient-friendly extemporaneous formulation of bisoprolol: application to stability and bioavailability studies.
El-Masry SM; Helmy SA; Helmy SAM; Mazyed EA
Drug Deliv Transl Res; 2023 Mar; 13(3):795-810. PubMed ID: 36192532
[TBL] [Abstract][Full Text] [Related]
9. Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding.
Zhao F; Dave VS; Mar MZ; Perri JR
Int J Pharm Compd; 2018; 22(5):433-439. PubMed ID: 30384342
[TBL] [Abstract][Full Text] [Related]
10. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
Glass BD; Haywood A
J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
[TBL] [Abstract][Full Text] [Related]
11. Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids.
Ghulam A; Keen K; Tuleu C; Wong IC; Long PF
Ann Pharmacother; 2007 May; 41(5):857-60. PubMed ID: 17440007
[TBL] [Abstract][Full Text] [Related]
12. Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days.
Svirskis D; Jaffer J; Agarwal P; Khan A; Kaur J; Cheng A; Hanning S
Int J Pharm Compd; 2020; 24(3):246-251. PubMed ID: 32401745
[TBL] [Abstract][Full Text] [Related]
13. Development of an extemporaneous oral liquid formulation of oxandrolone and its stability evaluation.
Garg A; Garg S; She RW
Burns; 2011 Nov; 37(7):1150-3. PubMed ID: 21764219
[TBL] [Abstract][Full Text] [Related]
14. Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan.
Musko M; Sznitowska M
Acta Pharm; 2014 Dec; 64(4):463-74. PubMed ID: 25531786
[TBL] [Abstract][Full Text] [Related]
15. Extemporaneous benznidazole oral suspension prepared from commercially available tablets for treatment of Chagas disease in paediatric patients.
García MC; Manzo RH; Jimenez-Kairuz AF
Trop Med Int Health; 2015 Jul; 20(7):864-70. PubMed ID: 25784402
[TBL] [Abstract][Full Text] [Related]
16. Preparation and stability evaluation of extemporaneous oral suspension of valsartan using commercially available tablets.
Zaid AN; Assali M; Qaddomi A; Ghanem M; Zaaror YA
Int J Pharm Compd; 2014; 18(2):169-74. PubMed ID: 24881122
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases.
Vanhoorne V; Peeters E; Van Tongelen I; Boussery K; Wynendaele E; De Spiegeleer B; Remon JP; Vervaet C
Orphanet J Rare Dis; 2019 Aug; 14(1):186. PubMed ID: 31370862
[TBL] [Abstract][Full Text] [Related]
18. Application of Accelerated Predictive Stability Studies in Extemporaneously Compounded Formulations of Chlorhexidine to Assess the Shelf Life.
González-González O; Ballesteros MP; Torrado JJ; Serrano DR
Molecules; 2023 Dec; 28(23):. PubMed ID: 38067654
[TBL] [Abstract][Full Text] [Related]
19. Excipient Stability in Oral Solid Dosage Forms: A Review.
Darji MA; Lalge RM; Marathe SP; Mulay TD; Fatima T; Alshammari A; Lee HK; Repka MA; Narasimha Murthy S
AAPS PharmSciTech; 2018 Jan; 19(1):12-26. PubMed ID: 28895106
[TBL] [Abstract][Full Text] [Related]
20. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4.
Polonini H; da Silva SL; Brandão MAF; Bauters T; De Moerloose B; Ferreira AO
Int J Pharm Compd; 2018; 22(6):516-526. PubMed ID: 30384353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
